Overview

Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of a randomized, double-blind, placebo-controlled, 2-way crossover study is to evaluate the efficacy, safety/tolerability and pharmacokinetics of JM-010 for the treatment of subjects with Parkinson's Disease (PD) with levodopa-induced dyskinesia (LID).
Phase:
Phase 2
Details
Lead Sponsor:
Bukwang Pharmaceutical
Collaborator:
Contera Pharma ApS
Treatments:
Levodopa